Armata Pharmaceuticals Share Price Today

Armata Pharmaceuticals secures $3.7M DoW funding for Phase 3 program

Armata Pharmaceuticals shares dropped 10.95% to $3.74 despite receiving $3.7 million in new DoW funding. Cumulative non-dilutive DoW funding for AP-SA02 reaches $32.4 million, with the latest tranche covering only 11.4%. Stock remains in a downtrend, trading 46.4% below its 200-day SMA with weak momentum scores. AP-SA02 targets complicated Staphylococcus aureus bacteremia, with Phase 3 studies planned for H2 2026.

Armata Pharmaceuticals posts $74.1M net income in Q2 2026 on non-cash gain

Armata Pharmaceuticals reported Q2 2026 net income of $74.1 million, driven by a $91 million non-cash gain from its Convertible Loan. Operating loss widened to $10.3 million as R&D and G&A costs rose. Grant revenue grew 15.7% YoY to $2.5 million. The company secured $28.7 million in total DoW funding and received FDA Fast Track designation for AP-SA02.

Armata advances AP-SA02 toward Phase 3 study with FDA submissions

Armata Pharmaceuticals, Inc. has submitted the complete Phase 3 protocol and responses to FDA feedback for AP-SA02, advancing the therapy toward a pivotal superiority study starting in the second half of 2026. The company completed four engineering runs and plans clinical trial material production. Additionally, Armata secured a $2.5 million continuation award from the U.S. Department of Defense, bringing total funding to $28.7 million, and promoted David House to chief financial officer.

Armata promotes David House to Chief Financial Officer

Armata has promoted David House to Chief Financial Officer from his previous role as Senior Vice President, Finance and Principal Financial Officer. The appointment, effective immediately, aims to secure financial leadership to drive the company's strategy and advance its clinical programs through late-stage development.

Armata secures $2.5M DoD funding for AP-SA02 Phase 3

Armata Pharmaceuticals, Inc. secured an additional $2.5 million in non-dilutive funding from the U.S. Department of Defense, bringing the total award to $28.7 million to support Phase 3 readiness for AP-SA02. The funding, managed by the Naval Medical Research Command, targets the development of a therapeutic for complicated Staphylococcus aureus bacteremia. The company plans to initiate a Phase 3 superiority study in the second half of 2026.